Arranta Bio, a Watertown, MA-based microbiome contract development and manufacturing organization (CDMO), completed an $82m funding round.
The round was completed with sole institutional investor Ampersand Capital Partners, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific, the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally.
Arranta will have access to Fisher Scientific’s full suite of products and services and will provide materials to Thermo Fisher for use in gene therapy production.
Formed in May 2019 by Mark Bamforth, CEO, and and Iain Baird, Arranta Bio provides live biopharmaceutical products (LBPs) for microbiome pioneers.
Specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome, the company offers the knowledge and resources necessary to help clients to develop and manufacture promising new microbiome therapies to meet the needs of patients.
The company, which is establishing late clinical and commercial-ready capacity at a new facility in Watertown, Massachusetts, USA, also added Steve Favaloro as Chief Financial Officer, and Lana Gladstein as Chief Legal Officer & General Counsel.